Skip to main content

Peer Review reports

From: Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

Original Submission
22 Nov 2022 Submitted Original manuscript
19 Dec 2022 Reviewed Reviewer Report
28 Dec 2022 Reviewed Reviewer Report
12 Jan 2023 Reviewed Reviewer Report
3 Mar 2023 Author responded Author comments - Danxia Zheng
Resubmission - Version 2
3 Mar 2023 Submitted Manuscript version 2
10 Mar 2023 Author responded Author comments - Danxia Zheng
Resubmission - Version 3
10 Mar 2023 Submitted Manuscript version 3
25 Mar 2023 Reviewed Reviewer Report
2 Apr 2023 Reviewed Reviewer Report
5 Apr 2023 Reviewed Reviewer Report
11 Apr 2023 Author responded Author comments - Danxia Zheng
Resubmission - Version 4
11 Apr 2023 Submitted Manuscript version 4
27 Apr 2023 Author responded Author comments - Danxia Zheng
Resubmission - Version 5
27 Apr 2023 Submitted Manuscript version 5
10 May 2023 Author responded Author comments - Danxia Zheng
Resubmission - Version 6
10 May 2023 Submitted Manuscript version 6
15 May 2023 Author responded Author comments - Danxia Zheng
Resubmission - Version 7
15 May 2023 Submitted Manuscript version 7
Publishing
18 May 2023 Editorially accepted
26 May 2023 Article published 10.1186/s12882-023-03206-1

You can find further information about peer review here.

Back to article page